E-EDV-D682

E-EDV-D682 (EDV-D682) is an EDV nanocell (bacterial minicell) drug conjugate developed by Engeneic Pty. Its target is EGFR (the sponsor names EGFR). The sponsor states: E-EDV-D682 packages the chemotherapeutic payload PNU-159682 inside a 400 nm, bacterially derived EnGeneIC EDV nanocell that is targeted to EGFR-expressing cancer cells via a bispecific antibody, delivering the payload directly into tumour cells. ClinicalTrials.gov describes the intervention as: E-EDV-D682 is a product based on the EnGeneIC EDV™ technology. EDVs are bacterially derived nanocells 400 nm in diameter that can be packaged with a range of different chemotherapeutic drugs and specifically targeted to cancer cell receptor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in pancreatic ductal adenocarcinoma. The largest, NCT07049055, plans to enrol 144 participants with primary completion expected 2028-09. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.